C-(5-methanesulfonyl-[2]thienyl)-methylamine | 706757-12-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: C-(5-methanesulfonyl-[2]thienyl)-methylamine
• 英文别名: C-(5-Methansulfonyl-[2]thienyl)-methylamin；(5-Methanesulfonylthiophen-2-yl)methanamine；(5-methylsulfonylthiophen-2-yl)methanamine
• CAS: 706757-12-2
• 化学式: C₆H₉NO₂S₂
• mdl: MFCD20703648
• 分子量: 191.275
• InChiKey: HBWPQQXFWIVESS-UHFFFAOYSA-N

物化性质

• 熔点：
  56 °C(Solv: ethyl ether (60-29-7))
• 沸点：
  398.4±42.0 °C(Predicted)
• 密度：
  1.359±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  96.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-(5-methanesulfonyl-[2]thienylmethyl)-phthalimide 在 乙醇 、 一水合肼 作用下， 生成 C-(5-methanesulfonyl-[2]thienyl)-methylamine
  参考文献：
  名称：

  潜在的噻吩化学疗法。第三部分 一些5-取代的2-噻吩基硫醚和砜

  摘要：

  DOI：

  10.1039/jr9540000237

文献信息

• [EN] AZAINDAZOLE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS<br/>[FR] COMPOSÉS AZAINDAZOLE EN TANT QU'ANTAGONISTES DES RÉCEPTEURS CCR1
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2010036632A1

  公开（公告）日：2010-04-01

  Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

  公开的是化合物的公式（I），用于治疗通过CCR1活性介导或维持的多种疾病和疾病，包括自身免疫性疾病，如风湿性关节炎和多发性硬化症。还公开了制备方法和使用方法。
• SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY
  申请人：OOST Thorsten

  公开号：US20140057920A1

  公开（公告）日：2014-02-27

  This invention relates to substituted 4-pyridones of formula 1 and their use as inhibitors of neutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  本发明涉及公式1的取代4-吡啶酮及其用作中性粒细胞弹性蛋白酶活性抑制剂的药物组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿生殖系统疾病、皮肤和眼睛炎症性疾病以及其他自身免疫和过敏性疾病、移植物排斥和肿瘤性疾病的方法。
• [EN] SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY<br/>[FR] 4-PYRIDONES SUBSTITUÉES ET LEUR UTILISATION COMME INHIBITEURS DE L'ACTIVITÉ DE L'ÉLASTASE NEUTROPHILE
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014029832A1

  公开（公告）日：2014-02-27

  P01-2864-ff 32/132 -132- ABSTRACT This invention relates to substituted 4-pyridones of formula R 1a R 7 R 6 R R 3 N O O N H R 4 R 2 R 1b A 1 and their use as inhibitors ofneutrophil elastase activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of pulmonary, gastrointestinal and genitourinary diseases, inflammatory diseases of the skin and the eye and other auto-immune and allergic disorders, allograft rejection, and oncological diseases.

  这项发明涉及化学式为R 1a R 7 R 6 R R 3 N O O N H R 4 R 2 R 1b A 1的取代4-吡啶酮，以及它们作为中性粒细胞弹性蛋白酶活性抑制剂的用途，含有相同化合物的制药组合物，以及将其用作治疗和/或预防肺部、胃肠道和泌尿系统疾病、皮肤和眼睛的炎症性疾病、其他自身免疫和过敏性疾病、移植物排斥反应和肿瘤性疾病的药剂的方法。
• Compound for the treatment of abnormal cell growth
  申请人：Pfizer Inc

  公开号：US20040220177A1

  公开（公告）日：2004-11-04

  The invention relates to compounds of the formula 1 1 and to pharmaceutically acceptable salts, prodrugs and solvates thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , n, A and B are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders, which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

  本发明涉及公式11的化合物，以及其药物可接受的盐、前药和溶剂化物，其中R1、R2、R3、R4、R5、n、A和B的定义如本文所述。本发明还涉及通过给予公式1的化合物治疗哺乳动物异常细胞生长的方法，并涉及用于治疗此类疾病的制药组合物，其中包含公式1的化合物。本发明还涉及制备公式1的化合物的方法。
• Azaindazole Compounds As CCR1 Receptor Antagonists
  申请人：COOK Brian Nicholas

  公开号：US20100093724A1

  公开（公告）日：2010-04-15

  Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are methods of making and methods of using same.

  本发明涉及式(I)化合物，其可用于治疗多种疾病和障碍，这些疾病和障碍是通过CCR1的活性介导或维持的，包括自身免疫性疾病，如类风湿性关节炎和多发性硬化症。同时，本发明还涉及制备方法和使用方法。